Evidence map›Paper›PMID 40444240›Full record

ReviewFrontiers in endocrinology2025

Recent advances in early diagnosis and treatment of T1D with miRNAs.

Xinling Zhang, Yuting Qiu, Dong-Ang Liu, Ruiyao Hu, Shiyu Chen, Yue Xu, Keyi Chen, Jinghua Yuan, Xiaoping Li

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Xinling ZhangKey Laboratory of Artificial Organs and Computational Medicine in Zhejiang Province, Shulan International Medical College, Zhejiang Shuren University, Hangzhou, China.
Yuting QiuKey Laboratory of Artificial Organs and Computational Medicine in Zhejiang Province, Shulan International Medical College, Zhejiang Shuren University, Hangzhou, China.
Dong-Ang LiuKey Laboratory of Artificial Organs and Computational Medicine in Zhejiang Province, Shulan International Medical College, Zhejiang Shuren University, Hangzhou, China.
Ruiyao HuKey Laboratory of Artificial Organs and Computational Medicine in Zhejiang Province, Shulan International Medical College, Zhejiang Shuren University, Hangzhou, China.
Shiyu ChenKey Laboratory of Artificial Organs and Computational Medicine in Zhejiang Province, Shulan International Medical College, Zhejiang Shuren University, Hangzhou, China.
Yue XuKey Laboratory of Artificial Organs and Computational Medicine in Zhejiang Province, Shulan International Medical College, Zhejiang Shuren University, Hangzhou, China.
Keyi ChenKey Laboratory of Artificial Organs and Computational Medicine in Zhejiang Province, Shulan International Medical College, Zhejiang Shuren University, Hangzhou, China.
Jinghua YuanKey Laboratory of Artificial Organs and Computational Medicine in Zhejiang Province, Shulan International Medical College, Zhejiang Shuren University, Hangzhou, China.
Xiaoping LiKey Laboratory of Artificial Organs and Computational Medicine in Zhejiang Province, Shulan International Medical College, Zhejiang Shuren University, Hangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Type 1 diabetes (T1D) is an autoimmune disease characterized by T cell-mediated destruction of pancreatic β-cells and is one of the most common chronic diseases in adults and children. In recent years, the incidence of T1D has been increasing worldwide. Currently, the diagnosis of T1D relies on clinical manifestations and autoantibody detection, with a lack of early predictive biomarkers. MicroRNAs (miRNAs), as crucial post-transcriptional regulatory factors, which are involved in various biological processes, including cell division, proliferation, differentiation, development, and metabolism. Additionally, miRNAs participate in the regulation of inflammatory complications in T1D, and their aberrant expression is closely associated with the disease. The stability of miRNAs makes them potential candidates for early diagnostic biomarkers and therapeutic targets in T1D. This paper discusses the pathogenesis of T1D and the potential applications of miRNAs in early diagnosis and interventional therapy. It provides references for advancing precision diagnosis and personalized treatment strategies through more profound miRNA research in the future.

Indexed as

Diabetes Mellitus, Type 1MicroRNAsAnimalsBiomarkersEarly DiagnosisHumansBiomarkersMicroRNAsbiomarkerscomplicationsdiagnosismiRNAsT1Dtreatment

Identifiers

PMID40444240
PMCPMC12119303

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.